A patient I’ve been following for about two years, fentanyl use disorder, stable on buprenorphine but never quite reaching full remission, BMI north of 38, hypertension managed poorly, told me last month that her primary care doctor started her on semaglutide for weight management. She came back six weeks later and mentioned, almost as an aside, that her cravings felt quieter. She wasn’t sure if it was the drug or just the fact that something in her life was finally going right. I didn’t know either. But I wrote it down.
I’ve seen this pattern more than once now across my patient panel, not controlled, not publishable, just a signal accumulating in the margins of my charts. So when a new preprint from bioRxiv landed this week showing that semaglutide attenuates intravenous fentanyl self-administration in female Wistar rats, it didn’t feel like a surprise. It felt like a confirmation that the field is finally asking the right question.
The Signal Behind the Rat Data
The study design deserves attention. Thirty-two female rats were implanted with jugular catheters and trained to self-administer fentanyl across 21 sessions under either short-access (one hour) or long-access (eight hours) conditions, a distinction that matters enormously, because long-access models produce escalating intake that better mirrors compulsive human use. Semaglutide reduced operant fentanyl-seeking across conditions. This builds on earlier preclinical work showing GLP-1 receptor agonists attenuate self-administration of other addictive substances, extending that mechanistic story directly into opioids.
The pharmacology is worth pausing on. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens, core nodes of the mesolimbic dopamine system. The working hypothesis is that GLP-1 agonism dampens reward salience broadly, not through mu-opioid receptor antagonism the way naltrexone works, but through a separate modulatory pathway that may affect how the brain encodes drug-seeking behavior. That mechanistic distinction matters clinically, because patients who fail naltrexone or struggle to sustain buprenorphine adherence may have reward-circuit dynamics that a GLP-1 approach could reach differently.
The cardiovascular safety profile of semaglutide in high-risk metabolic populations also adds clinical plausibility here. In the SELECT trial, semaglutide produced a meaningful reduction in major adverse cardiovascular events, and the OUD population carries disproportionate metabolic burden, hypertension, and cardiovascular risk from years of substance use and healthcare avoidance. A drug that might reduce opioid craving while simultaneously improving the cardiometabolic profile of a patient who hasn’t seen a doctor in years is not a trivial overlap. The SELECT data wasn’t designed with OUD in mind, but the patient profile rhymes.
The 74.9% the Field Keeps Ignoring
Here’s the number that should sit at the center of every OUD pipeline discussion: according to CDC’s 2022 MMWR data, only 25.1% of the estimated 9.4 million U.S. adults who needed OUD treatment actually received medications for it. Buprenorphine dominates the existing treatment market, holding 59.58% of a global OUD market estimated at $5.3 billion in 2024, and yet three in four people who need treatment aren’t getting any approved pharmacotherapy at all. That gap has structural causes: stigma, prescriber shortages, prior authorization barriers, and the real lived experience of patients who’ve tried buprenorphine or methadone and stopped because of side effects, logistics, or the social friction of clinic-based dispensing.
A GLP-1 approach, if it translates, enters a completely different prescriber ecosystem. Semaglutide is already FDA-approved since June 2021 for chronic weight management. Primary care physicians and endocrinologists prescribe it at massive scale. The patients who have comorbid obesity, metabolic syndrome, and OUD, a population I see regularly across my telehealth panel, could theoretically access a GLP-1 intervention through a care relationship that carries none of the stigma associated with addiction treatment. That is not a small thing.
What the trial design community needs to grapple with is how to study this honestly. The rat data is sex-specific, female Wistar rats, which is actually a methodologically important choice given that female rodents often show faster escalation of drug intake. But human OUD trials have historically over-enrolled men, and the sex-stratified signal in this preclinical work argues for prospective stratification from the start, not a post-hoc subgroup analysis. Beyond that, the endpoint question is real: if GLP-1 agonism reduces craving and drug-seeking through a reward-salience mechanism, patient-reported craving scales and fentanyl urine toxicology should both be co-primary. Relying on abstinence alone as the primary endpoint risks missing a harm-reduction-relevant signal in patients who reduce use substantially but don’t achieve full abstinence, which, in my clinical experience running SUD trials, represents the majority of meaningful treatment response in this population. English-only recruitment protocols will also systematically exclude the Spanish-speaking fentanyl patients I treat through our telehealth program, who are already invisible in the OUD evidence base.
What I’m Watching Next
The field is moving toward human pilot data, and it needs to move faster. I’ll be watching for any Phase 2 signal on GLP-1 agonists in OUD that includes craving endpoints alongside biomarkers, and for whether any sponsor is bold enough to enroll the dual-diagnosis, high-BMI, fentanyl-exposed patient that the preclinical model is actually describing.
References
- bioRxiv: “Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats”
- CDC MMWR: “Receipt of Medications for Opioid Use Disorder Among Adults Needing Treatment, United States, 2022”
- FDA: Wegovy (semaglutide) Approval for Chronic Weight Management, June 4, 2021
- NEJM: SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity
- Grand View Research: Opioid Use Disorder Treatment Market Size Report, 2024
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
